Apollomics, Inc. (NASDAQ:APLMW) Sees Significant Drop in Short Interest

Apollomics, Inc. (NASDAQ:APLMW) saw a significant decrease in short interest in October. As of October 31st, there was short interest totalling 53,800 shares, a decrease of 17.2% from the October 15th total of 65,000 shares. Based on an average trading volume of 22,000 shares, the short-interest ratio is currently 2.4 days.

Apollomics Stock Up 5.2 %

NASDAQ:APLMW traded up $0.00 during trading on Friday, reaching $0.01. The company’s stock had a trading volume of 317 shares, compared to its average volume of 32,298. Apollomics has a 12 month low of $0.01 and a 12 month high of $0.06. The firm has a 50 day moving average of $0.01 and a 200-day moving average of $0.01.

Apollomics Company Profile

Apollomics, Inc, a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways.